Added 1 day ago Drug news

FDA Advisory Commmittee recommends baricitinib 2-mg dose to treat Rheumatoid Arthritis but not 4-mg dose.- Eli Lilly + Incyte Corpn.

Eli Lilly and Company and Incyte Corporation announced that the FDA Arthritis Advisory Committee recommended approval of the 2-mg dose...

Added 5 days ago Drug news

NICE gives final opinion approving use of RoActemra in giant cell arteritis.- Roche/Chugai.

In final guidance, the National Institute of Health and Care Excellence has given its support for the use of RoActemra...

Added 11 days ago Drug news

Positive Phase III SELECT-COMPARE study of upadacitinib for rheumatoid arthritis.-Abbvie.

AbbVie has announced positive top-line results from the Phase III SELECT-COMPARE clinical trial showing that after 12 weeks, upadacitinib (15...

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

The aim of this guideline was to produce recommendations for the management of adult lupus patients in the UK that cover the diagnosis, assessment and monitoring of lupus and the treatment of mild, moderate and severe active lupus disease...

Added 1 month ago

The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome

This document aims to provide a pragmatic, practical guideline for the management of adults with pSS.

Added 1 month ago

The British Society for Rheumatology Guideline for the Management of Gout

This guideline aims to offer revised and updated, concise, patient-focused, evidence-based, expert recommendations for the management of gout in the UK.

Added 1 month ago

Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.

Objective: To investigate maintenance of rituximab (RTX) in RA patients re-treated with reduced doses compared with standard dose in a real life setting.

Added 2 months ago

Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.

The objective of this study is to explore the following: (1) the impact of two different initial doses and cumulative 2-year dose of rituximab (RTX) on drug adherence and predictors of adherence to treatment in rheumatoid arthritis (RA)...

Added 2 months ago

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.

Introduction: Rheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients.

Added 2 months ago

Inhibition of Co-Stimulation in Rheumatoid Arthritis (ICoSRA)

The purpose of this study is to use abatacept as a clinical molecular probe to evaluate the effects of inhibiting...

Added 3 years ago

A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

This is a phase 3, randomized, double-blind study comparing ABT-494 to Placebo and to Adalimumab in subjects with moderately to...

Added 3 years ago

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Primary Objective:
- To demonstrate that sarilumab monotherapy is superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28...

Added 4 years ago